Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

141. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding

Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

142. Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication

Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

143. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses

Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

144. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials

Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Mcquaid K R, Laine L CRD summary This review assessed proton-pump inhibitors for the relief of heartburn within 1 to 2 days. The authors concluded that proton pump (...) inhibitors may improve symptoms within 24 hours, but most patients will not experience relief in the first 1 or 2 days. Apart from the limited search, this was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of proton-pump inhibitors (PPIs) for heartburn relief within the first 1 to 2 days of treatment. Searching MEDLINE (1966 to June 2004) and EMBASE (1980 to June 2004) were searched without language restrictions; the search

2005 DARE.

145. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK

Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Remak E, Brown R E, Yuen C, Robinson A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) to treat gastro-oesophageal reflux disease (GORD). Seven PPIs were compared. These were esomeprazole, lansoprazole capsules, lansoprazole oro-dispersible tablets, omeprazole (generic and branded), pantoprazole and rabeprazole. Type of intervention

2005 NHS Economic Evaluation Database.

146. 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan

'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S (...) on a first-line proton-pump inhibitor (PPI), lansoprazole 30 mg/day (LAN), for 8 weeks (plus a further 12 weeks for unhealed patients). The other was a step-up approach in which patients started with a histamine H2-receptor antagonist (H2RA), ranitidine 300 mg/day (RAN), for 8 weeks and then switched to LAN in case of failure. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients

2005 NHS Economic Evaluation Database.

147. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease

Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

148. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Hughes D, Bodger K, Bytzer P, De Herdt D, Dubois D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several on-demand maintenance therapies with oral proton-pump inhibitors (PPIs) in patients with endoscopy-confirmed non-erosive reflux disease (NERD). The PPIs studied were esomeprazole 20 mg, lansoprazole 15 mg, omeprazole 10 and 20 mg

2005 NHS Economic Evaluation Database.

149. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding Full Text available with Trip Pro

The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding Barkun A N, Herba K, Adam V, Kennedy W, Fallone C A, Bardou M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of high-dose oral and intravenous (i.v.) proton-pump inhibitors (PPIs) for the treatment of selected patients with acute gastro-duodenal ulcer bleeding following successful endoscopic therapy for high-risk lesions. High-dose

2004 NHS Economic Evaluation Database.

150. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis

' conclusions The study supported the routine use of high-dose proton-pump inhibition (HDPPI) therapy for patients with bleeding ulcers who had undergone endoscopic treatment. CRD COMMENTARY - Selection of comparators No HDPPI was chosen as the comparator. This seems to have been an acceptable alternative for the health technology under investigation (i.e. treatment with HDPPI). Pantoprazole was considered in the HDPPI option because it was the only intravenous proton-pump inhibitor that was widely (...) High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients

2004 NHS Economic Evaluation Database.

151. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?

Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

152. Effectiveness of proton pump inhibitors in nonerosive reflux disease

Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Dean B B, Gano A D, Knight K, Ofman J J, Fass R CRD summary This review assessed the use of proton-pump inhibitors (PPIs) to relieve the symptoms of nonerosive reflux disease (NERD). The authors concluded that PPIs have a lesser effect in NERD than in erosive oesophagitis, and that symptoms (...) tended to improve throughout the 4-week period. Insufficient data were presented to assess the appropriateness of pooling the studies, hence any conclusions may not be reliable. Authors' objectives To assess the effectiveness of proton-pump inhibitors (PPIs) for the relief of symptoms of nonerosive reflux disease (NERD), and also to assess the effects of PPIs in patients with NERD compared with patients with erosive oesophagitis (EE). Searching MEDLINE and HealthSTAR were searched for studies

2004 DARE.

153. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics

Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Numans M E, Lau J, de Wit N J, Bonis P A CRD summary (...) This review assessed the accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment in the diagnosis of gastroesophageal reflux disease (GERD). The authors concluded that a response to short-term treatment with PPIs does not accurately diagnose GERD as defined by traditional objective criteria. The authors' conclusions are likely to be reliable. Authors' objectives To determine the diagnostic accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment as an indicator

2004 DARE.

154. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis Moayyedi P, Delaney B C, Vakil N, Forman D, Talley N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) in adult patients with nonulcer dyspepsia (NUD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of adult patients with symptoms of dyspepsia, negative findings on endoscopy

2004 NHS Economic Evaluation Database.

155. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding

Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Erstad B L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of adjunctive oral and intravenous proton-pump inhibitor (PPI) therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalisation. Four clinical scenarios were considered. Scenario 1 was diagnostic endoscopy and oral PPI therapy (40 mg twice daily of omeprazole or the equivalent dose of another PPI for 5 days). Scenario 2

2004 NHS Economic Evaluation Database.

156. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use

Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use Klok R M, Postma M J, Van Hout B A, Brouwers J R CRD summary This review compared the effectiveness of different proton-pump inhibitors in the management of gastro-oesophageal reflux disease, peptic ulcer disease and Heliocobacter pylori. The authors (...) concluded that the differences found may be due to the high dose used and not the specific inhibitor. Given the lack of information on differences between the studies and the quality of the individual studies, it is difficult to verify the conclusions. Authors' objectives To compare the efficacy of proton-pump inhibitors (PPIs) in the short-term management of gastro-oesophageal reflux disease (GERD), peptic ulcer disease PUD), and the eradication of Helicobacter pylori (H. pylori). Searching MEDLINE

2003 DARE.

157. Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication

Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Meta-analysis. Proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication Gisbert J P, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares J M CRD summary This meta (...) -analysis assessed the effectiveness of proton-pump inhibitors and H2-receptor antagonists, both co-prescribed with antibiotics, in Helicobacter pylori eradication. The authors concluded that proton-pump inhibitors are more effective than H2-receptor antagonists when prescribed at usual doses. The authors' conclusion is consistent with the evidence reviewed, and is likely to be reliable. Authors' objectives To perform a meta-analysis comparing the efficacy of proton-pump inhibitors (PPIs) and H2

2003 DARE.

158. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication Vergara M, Vallve M, Gisbert J P, Calvet X CRD summary This review compared the efficacy of different proton-pump (...) inhibitors (omeprazole, lansoprazole, rabeprazole and esomeprazole) in standard triple therapy for Helicobacter pylori eradication. The authors concluded that there appears to be no difference in the efficacy of different proton-pump inhibitors. The authors' conclusions are likely to be reliable. Authors' objectives To compare the efficacy of different proton-pump inhibitors (PPIs) in triple therapy for Helicobacter pylori (H. pylori) eradication. Searching MEDLINE was searched in September 2002

2003 DARE.

159. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease

Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer (...) disease Vakil N, Fennerty M B CRD summary This review assessed the efficacy of proton-pump inhibitors in treating gastro-oesophageal reflux and peptic ulcer disease, and concluded that insufficient evidence was available to establish the superiority of any one agent. A limited search and language restrictions mean that studies might have been missed. The broad conclusion seems appropriate, however, the specific conclusions and implications for practice should be treated with caution. Authors

2003 DARE.

160. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis

Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis You J H, Lee A C, Wong S C, Chan F K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared standard-dose histamine-2 receptor antagonist (H2RA), low-dose proton-pump inhibitor (PPI) and standard-dose PPI as maintenance therapy in patients with gastrooesophageal reflux disease (GERD

2003 NHS Economic Evaluation Database.